ArticleMedical journal of the Islamic Republic of Iran2025
Epidemiological Profile of Adult Hematopoietic Stem Cell Transplantation for Malignant Diseases: Experience from a Reference Service in Urmia, Iran (2010-2024).
Article in Medical journal of the Islamic Republic of Iran, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematopoietic stem cell transplantation (HSCT) is a critical therapeutic option for patients with specific malignancies. This study aimed to elucidate the epidemiological profile of HSCT to address existing gaps in understanding regional trends and outcomes over 14 years at a single center. Methods: This retrospective cohort study analyzed the medical records of all patients who underwent HSCT at the Bone Marrow Transplant (BMT) ward of Urmia Imam Khomeini Hospital in Iran, from December 2010 to December 2024. Comprehensive evaluations of clinical and demographic characteristics were conducted during the pre-HSCT period. Data collection focused on post-transplant clinical outcomes and complications, adhering to standardized definitions to ensure unbiased estimates. Results: This study examined 280 HSCT patients, predominantly men (59.6%), with a mean age of 45.85 years (SD, 13.70). Autologous HSCT comprised 76.43% of cases, followed by allogeneic (21.78%) and haploidentical donor HSCT (1.79%). The primary indications were multiple myeloma (48.9%) and acute myeloid leukemia (24.3%). The median overall survival (OS) was 77 months (95% CI: 62.05-91.95), and a 5-year OS rate of 54%. The mean disease-free survival (DFS) was 86.21 months (95% CI: 74.62-97.81), with a 5-year DFS rate of 67%. The cumulative incidence of acute graft-versus-host disease (acute GVHD) was 59.2% at 100 days post-transplant (61% in allogeneic and 40% in haploidentical patients), with skin being the most affected organ (78.12%). Last, 20.2% of the mortality in the total population with available acute GVHD was attributed to having grades 3 and -4 acute GVHD. Conclusion: These findings underscore the viability of hematopoietic stem cell transplantation in resource-limited settings, highlight areas for improvement in post-transplant care-particularly regarding severe acute GVHD-and offer valuable insights to guide clinical practice and health policy in similar regional centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.